

REMARKS


Claims 1-23 were pending and stand rejected. Applicant acknowledges the Examiner's withdrawal of the § 103 rejections. The only remaining rejection involves the Examiner's concern of the term TNF in the claims. While the Examiner admits that the specification enables claims directed to TNF- α , the Examiner maintains that the specification is not enabling for all types of TNF (e.g. TNF- β).

Without agreeing with the Examiner, applicant directs the Examiner's attention to the phrase "recombinant human Tumor Necrosis Factor Alpha, (TNF α or just TNF)" on page 7 of the specification. Clearly, this phrase indicates that "TNF" is meant to indicate TNF α . Thus, no amendments should be needed. Nonetheless, to further the prosecution, and without acquiescing to the Examiner's argument, and hereby reserving the right to prosecute the unamended (or similar) claims, Claims 1, 7 and 19 have been amended to indicate they are directed to TNF α .

CONCLUSION

For the reasons set forth above, Applicant respectfully submits that all pending claims are currently in condition for allowance. Should the Examiner believe that a telephone interview would aid in the prosecution of this application, Applicants encourage the Examiner to call the undersigned collect at (617) 252-3353.

Dated: November 27, 2000


Peter G. Carroll
Registration No. 32,837

MEDLEN & CARROLL, LLP
220 Montgomery Street, Suite 2200
San Francisco, California 94104